Scores and History of the research laboratory
2020-dated Stanford analysis: RF in top 2% scientists (Ioannidis et al., 2020: doi:10.1371/journal.pbio.3000918). In 1% (0.3%) top-rated experts in Alzheimer's Disease (AD) 2011-2021 (https://expertscape.com)
Researcher ID: C-3694-2015.
"All" Research sexenios:6.
"All" Techtransfer sexenios:1.
End 2021-dated: Publications: >470 (350 in Q1). h-index=78 (Scopus), 90 (real). Citations:19K (Scopus) >22K (Res Gate) Last 5 years: >1200 citations/year.
History
Founder of GPCR Mol Res lab (after 1985 stay in Prof Burnstock's lab). Describing first GPCR heteromer (Het) formed by 2 receptors for 2 neurotransmitters. Later: i) development of nomenclature & technology in the field ii) reporting Het disruption in neurodegenerative disease & iii) the first reliable structure of a heterotetramer coupled to 1 Gs & 1 Gi protein
The interaction between AR types broadens the physiological perspective of GPCRs, the A2A-A2BHet is a recent example increasing knowledge of Immune function & allowing to better understand physiological aging & the role of brown adipocytes in obesity (papers: Oncotarget & Cell Metabolism)
Since 1988 Franco's lab has received continued support (competitive tenders by public or private bodies), mainly for research on GPCRs, with focus on CNS function & potential as targets for neurological & neuropsychiatric diseases & drug addiction. The last three MICINN/AEI & the "Heteropark" Eranet-neuron (coordinator of 4 labs) projects related to GPCR Hets
2009-2013: Head of lab in CIMA (Pamplona): developing GPCR platform with CIMA proprietary molecules for translational research in PD & AD. Franco's CIMA members co- inventors of patents, the scientific production increased qual/quantitatively.
2014- Back as Professor in UB (head of Mol Neurobiol laboratory)
(Other Merits)